The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

Logo poskytovatele
Logo poskytovatele

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.

Autoři

PANOVSKÁ Anna SMOLEJ L. LYSÁK D. BRYCHTOVÁ Yvona ŠIMKOVIČ M. MOTYČKOVÁ M. VODÁREK P. LINDTNEROVÁ Michaela TRBUŠEK Martin MALČÍKOVÁ Jitka POSPÍŠILOVÁ Šárka MAYER Jiří DOUBEK Michael

Rok publikování 2013
Druh Článek v odborném periodiku
Časopis / Zdroj European Journal of Haematology
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
Doi http://dx.doi.org/10.1111/ejh.12106
Obor Onkologie a hematologie
Klíčová slova chronic lymhocytic leukemia; FRC chemoimmunotherapy; relapse; survival
Přiložené soubory
Popis Background There is minimal data about the efficacy of subsequent therapy in patients with relapse after FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy. Methods We retrospectively analyzed the outcomes of 119 patients who relapsed after standard-dose FCR. The patient cohort consisted of patients who relapsed after FCR administered as first-line therapy (Group 1, n=63) and patients relapsing after FCR administered in second/subsequent line; (Group 2, n=56). Results Basic parameters (age, clinical stage, cytogenetics, molecular genetics) did not differ significantly between these subgroups. Likewise, median progression-free survival (PFS) was not considerably different after FCR (18.6 vs. 14.7 months). Subsequent therapy for relapsed disease included FCR retreatment, R-CHOP, alemtuzumab, or rituximab plus high-dose dexamethasone. Overall response rates for the two groups did not significantly differ (59% vs. 44%). Although PFS after subsequent therapy was relatively short, longer PFS was observed in Group 1 (13.3 vs. 5.9 months; P=0.01), in patients with response duration 24 months after previous FCR (13 vs. 6.1 months; 0.01), and in patients who achieved complete remission after FCR (10.8 vs. 7.9 months in partial remission; P=0.01). Newly detected 17p deletions were observed in 5/62 patients, and new p53 mutations in 6/34 FCR-treated patients. Conclusion Our data indicate that the prognosis of patients who relapse after FCR remains poor regardless of the subsequent treatment regimen.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info